Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Target molecules for anti-angiogenic therapy: from basic research to clinical trials
Autore:
Hagedorn, M; Bikfalvi, A;
Indirizzi:
Univ Bordeaux 1, Growth Factor & Cell Differenciat Lab, F-33405 Talence, France Univ Bordeaux 1 Talence France F-33405 ciat Lab, F-33405 Talence, France
Titolo Testata:
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
fascicolo: 2, volume: 34, anno: 2000,
pagine: 89 - 110
SICI:
1040-8428(200005)34:2<89:TMFATF>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Soggetto:
ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; SUPPRESSES TUMOR-GROWTH; PLATELET FACTOR-IV; ACTIVATOR INHIBITOR TYPE-1; HUMAN BREAST-CARCINOMA; LEWIS-LUNG-CARCINOMA; ALPHA-V INTEGRINS; X-C CHEMOKINES; ARG-GLY-ASP;
Keywords:
angiogenesis; endothelial cell; clinical trial; angiogenesis inhibitor;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
224
Recensione:
Indirizzi per estratti:
Indirizzo: Bikfalvi, A Univ Bordeaux 1, Growth Factor & Cell Differenciat Lab, Batiment Rech BiolAnim,Ave Fac, F-33405 Talence, France Univ Bordeaux 1 Batiment Rech Biol Anim,Ave Fac Talence France F-33405
Citazione:
M. Hagedorn e A. Bikfalvi, "Target molecules for anti-angiogenic therapy: from basic research to clinical trials", CR R ONC H, 34(2), 2000, pp. 89-110

Abstract

There is growing evidence that anti-angiogenic drugs will improve future therapies of diseases like cancer, rheumatoid arthritis and ocular neovascularisation. However: it is still uncertain which kind of substance, out of the large number of angiogenesis inhibitors, will prove to be a suitable agent to treat these human diseases. There are currently more than 30 angiogenesis inhibitors in clinical trials and a multitude of promising new candidates are under investigation in vitro and in animal models. Important therapeutic strategies are: suppression of activity of the major angiogenic regulators like vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); inhibition of function of alpha v-integrins and matrix metalloproteinases (MMPs); the exploitation of endogenous anti-angiogenic molecules like angiostatin, endostatin or thrombospondin. Given the wide spectrum of diseases which could be treated by anti-angiogenic compounds, it Is important for today's clinicians to understand their essential mode of action at a cellular and molecular level. Here we give an in-depth overview of the basic pathophysiological mechanisms underlying the different anti-angiogenic approaches used to date based on the most recent fundamental and clinicalresearch data. The angiogenesis inhibitors in clinical trials are presented and promising future drug candidates are discussed. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 11/07/20 alle ore 20:32:26